ACADIA Pharmaceuticals Inc. (ACAD.W)
1.34USD
5 Feb 2010
$0.03 (+2.36%)
$1.34
--
$1.32
$1.25
383,078
673,609
$6.60
$0.75
ACAD.W
About
Overall
| Beta: | 2.27 |
| Market Cap (Mil.): | $49.75 |
| Shares Outstanding (Mil.): | 38.27 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| ACAD.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 25.40 | -- | -- |
| ROI: | -91.48 | 1.25 | 2.30 |
| ROE: | -118.34 | 2.09 | 2.82 |
UPDATE 2-Acadia, Biovail plan more study on Parkinson's drug
* To pursue adjunctive therapy with drug for schizophrenia
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 6
(Updates to after the open, adds Exxon, Chatten, Marshall, Acadia/Biovail)
STOCKS NEWS US-FBR cuts Q3 earnings view on M. Stanley in half
U.S. stock market report [.N] 0846 ET 06Oct2009-FBR cuts Q3 earnings view on Morgan Stanley in half ------------------------------------------------------------------------------
STOCKS NEWS US-Exxon agrees to buy stake in Jubilee field
U.S. stock market report [.N] 0838 ET 06Oct2009-Exxon agrees to buy stake in Jubilee field ------------------------------------------------------------------------------
STOCKS NEWS US-Retail group sees US holiday sales off 1 pct
U.S. stock market report [.N] 0830 ET 06Oct2009-Retail group sees U.S. holiday sales down 1 pct ------------------------------------------------------------------------------
BEFORE THE BELL-Acadia to stage third trial for pimavanserin
NEW YORK, Oct 6 (Reuters) - Acadia Pharmaceuticals Inc shares jumped 20.6 percent to $1.99 in premarket on Tuesday after giving details on plans for its experimental Parkinson's disease treatment pimavanserin.
STOCKS NEWS US-Acadia, Biovail plan more study on drug
U.S. stock market report [.N] 0822 ET 06Oct2009-Acadia, Biovail plan more study on drug ------------------------------------------------------------------------------
CANADA STOCKS-TSX may get boost at open from commodity rally
TORONTO, Oct 6 (Reuters) - Toronto's main stock index could open higher on Tuesday as the resource-heavy index may draw support from the rally in prices for gold and oil.
UPDATE 3-Acadia psychosis drug misses main goal; shrs sink
* Acadia shares sink 68 pct; Biovail down 2 pct (Adds analyst comment, bylines; updates shares)
HEADLINE STOCKS-Some U.S. stocks on the move on Sept. 1
(Updates to after the open, adds Novavax, America's Car-Mart, Builders, Gander, Icagen, Sotheby's)
Competitors
| Price | Change | |
|---|---|---|
| AstraZeneca plc (AZN.L) | £2,823.50 | +8.00 |
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Johnson & Johnson (JNJ.N) | $62.76 | +0.39 |
| Bristol Myers Squibb Co. (BMY.N) | $24.25 | +0.29 |
| Bristol Myers Squibb Co. (BMY_p.N) | $439.50 | 0.00 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| Allergan, Inc. (AGN.N) | $58.75 | +0.58 |
| Sanofi-Aventis SA (SASY.PA) | €53.33 | +0.67 |
| Sepracor Inc. (SEPR.OQ) | -- | -- |
| King Pharmaceuticals, Inc. (KG.N) | $11.44 | +0.14 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
